Publications by authors named "R Woodford"
The incidence of gastroesophageal cancers is rising, driven, in part, by an increasing burden of risk factors of obesity and gastroesophageal reflux. Despite efforts to address these risk factors, and a growing interest in methods of population screening, the bulk of these tumours are unresectable at diagnosis. In this setting, effective systemic treatments are paramount to improve survival and quality of life.
View Article and Find Full Text PDFIntroduction: Approximately 50 % of resected stage II-IV melanoma patients develop recurrent disease by 5 years despite adjuvant anti-PD-1 therapy. Data to define best management of recurrences is lacking.
Methods: This was a multicentre, international, retrospective cohort study.
The superior productivity of C plants is achieved via a metabolic C cycle which acts as a CO pump across mesophyll and bundle sheath (BS) cells and requires an additional input of energy in the form of ATP. The importance of chloroplast NADH dehydrogenase-like complex (NDH) operating cyclic electron flow (CEF) around Photosystem I (PSI) for C photosynthesis has been shown in reverse genetics studies but the contribution of CEF and NDH to cell-level electron fluxes remained unknown. We have created gene-edited Setaria viridis with null ndhO alleles lacking functional NDH and developed methods for quantification of electron flow through NDH in BS and mesophyll cells.
View Article and Find Full Text PDFArticle Synopsis
- Anti-PD-1 antibodies and BRAF/MEK inhibitors can help reduce recurrence risk in resected stage III melanoma patients, and the study investigated the effectiveness of a 'second adjuvant' BRAF/MEKi therapy for those who experienced recurrence after initial treatment.
- A total of 73 BRAFmut melanoma patients were analyzed, with 61 receiving 'second adjuvant' therapy and showing significant improvements in recurrence-free survival (RFS) compared to those who didn’t receive this treatment.
- While the second adjuvant therapy led to better RFS, it also resulted in high rates of toxicity, prompting a need for further research on treatment strategies to enhance outcomes while minimizing side effects.
Purpose: Progression-free survival (PFS)-2, defined as the time from randomization to progression on second-line therapy, is potentially a more reliable surrogate than PFS for overall survival (OS), but will require longer follow-up and a larger sample size. We sought to compare the validity and efficiency, defined as proportional increase in follow-up time and sample size, of PFS-2 to PFS.
Methods: We performed an electronic search to identify randomized trials of advanced solid tumors reporting PFS, PFS-2, and OS as prespecified end points.